The Evidence MultiStat biochip analyzer is a product of Randox (Crumlin, UK). In addition to cardiac tests, it offers arrays for stroke, metabolic syndrome, cancer, fertility disorders, thyroid disorders, synthetic steroids, and drugs of abuse. The Evidence MutiStat belongs to a family of flexible and reliable immunoassay analyzers. The largest member of the family is the Evidence, which has an output of 1,400 tests per hour.

The MutiStat system is suitable for emergency departments, cardiac units, doctor's surgeries, forensic units, rehabilitation units, and employee drug screening centers. The technology offers fully automated pipetting, incubation, washing, imaging, and report generation. This, together with a user-friendly touch screen and Windows-based software, enables the MultiStat to be used by nontechnical staff with little or no training.

The test menu can work with a wide range of sample matrix including urine and serum--plasma and whole blood are currently in development. The cardiac arrays include creatinine kinase-MB (CK-MB), fatty acid binding protein (FABP), myoglobin, and cardiac troponin. The drugs of abuse arrays include multiple analytes such as amphetamine, barbiturates, benzadiazepine, cannabinoids, and cocaine.

Cardiovascular disease is a progressive and complicated condition, covering a range of symptoms and biochemical processes that vary according to the patient. Multiple markers are therefore required to provide accurate diagnoses. The new Randox technology benefits patients with chest pains by rapidly identifying risk and enabling accurate clinical decisions.

Randox is a diagnostics company that develops, manufactures, and markets clinical diagnostic products worldwide. Its core products include biochip array technology; clinical chemistry analyzers and reagents; quality controls; recombinant proteins and antibodies.

Related Links:
Randox